RedHill Biopharma, a specialty biopharmaceutical company with a focus on developing treatments for the bacterial infection H. pylori, has renewed its contract with Medi-Cal, California’s Medicaid healthcare program.
Under the agreement, H. pylori medication Talicia will not require prior authorization and will have a $0 copay for Medi-Cal patients, according to an Oct. 1 press release.
Talicia has been listed by Medi-Cal since 2021, making it available to 15 million Californian patients.
In healthcare’s dynamic regulatory and economic environment, leaders of gastroenterology-focused ASCs are keeping close tabs on industry developments. Here are…
Approximately 1 in 26 women will be diagnosed with colorectal cancer in their lifetime. Despite this, many women may mistake…
Gastroenterologists are facing increasing financial strain as reimbursement rates continue to decline. A study published in The American Journal of…
